PRRT is a targeted cancer treatment that combines a peptide that binds to specific receptors on tumors with a radioactive substance to deliver radiation directly to cancer cells.
The therapy uses radiolabeled peptides that target somatostatin receptors, which are overexpressed on certain tumor cells, particularly neuroendocrine tumors (NETs).
The most common agent is **lutetium-177 (Lu-177) dotatate** (brand name Lutathera).
When injected, the peptide acts like a homing device, seeking out and binding to receptors on tumor cells.
The attached radioactive isotope then delivers targeted radiation to destroy the cancer cells while minimizing damage to surrounding healthy tissue.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the main approved indication.
Progressive, well-differentiated, somatostatin receptor-positive tumors with advanced or metastatic disease
Typically involves 4 doses given at 8-week intervals, administered through IV infusion.
Patients also receive amino acid infusions to protect the kidneys, which can absorb some of the radioactive material.
Tumor shrinkage or stabilization occurs in many patients
Improved progression-free survival
Generally well-tolerated with manageable side effects
Targets tumors throughout the body simultaneously Common Side Effects
Nausea and vomiting Fatigue Decreased blood cell counts Kidney and liver function changes